News Conference News CRT 2017 Higher Mortality Among TAVR Patients With Atrial Fibrillation Treated With Triple Therapy Michael O'Riordan February 20, 2017
News Daily News Unique Scar in RVOT May Trigger Ventricular Tachycardia Seen in High-Level Endurance Athletes Michael O'Riordan January 31, 2017
News Features The Prickly Problem of Permanent Pacing After TAVR: One Hospital Pitches a Protocol Michael O'Riordan January 24, 2017
News Features Be It Resolved: How Alcohol Harms or Helps the Heart Remains Controversial—and Confusing Shelley Wood January 04, 2017
News Daily News Best Anticoagulant in the TAVR Patient With A-fib? Small Study Makes Case for Apixaban Michael O'Riordan January 03, 2017
News Features Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond Shelley Wood December 30, 2016
News Features Repaso del Año: Los Médicos Eligen las Noticias Más Importantes de 2016 en Cardiología Intervencionista y Más Shelley Wood December 30, 2016
News Daily News Avoid Simvastatin, Lovastatin in Dabigatran-Treated Patients, Analysis Suggests Todd Neale November 24, 2016
Presentation AHA 2016 PIONEER Trial: An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy Presenter: Michael Gibson November 15, 2016
News Conference News AHA 2016 Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI Todd Neale November 14, 2016
News Conference News AHA 2016 AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR Shelley Wood November 09, 2016
Presentation TCT 2016 The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status Presenter: Freek W.A. Verheugt, Pascal Vranckx, C. Michael Gibson November 01, 2016
Presentation TCT 2016 Acute Anticoagulation Management and Bleeding Avoidance Strategies in the Chronic AF Patient Who Requires PCI Presenter: David P. Faxon, C. Michael Gibson, Deepak L. Bhatt November 01, 2016
Presentation TCT 2016 When and Which Antiplatelet Agent Should be Dropped When Using Oral Anticoagulant Therapy? Presenter: David P. Faxon, C. Michael Gibson, Roxana Mehran November 01, 2016
Presentation TCT 2016 Dosing Considerations of Oral Anticoagulant Therapy in the ACS and PCI Patient: Optimizing Efficacy While Minimizing Bleeding Presenter: David P. Faxon, C. Michael Gibson November 01, 2016
Presentation TCT 2016 General Overview and Highlights of the North American Consensus Document on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI Presenter: David P. Faxon, C. Michael Gibson, Dominick J. Angiolillo November 01, 2016
Presentation TCT 2016 European Guidelines on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI Presenter: David P. Faxon, C. Michael Gibson, Davide Capodanno November 01, 2016
Presentation TCT 2016 What Is Known (and What Is Not) About Discontinuing Aspirin or Clopidogrel in Patients on Chronic Oral Anticoagulants Plus DAPT Presenter: David P. Faxon, C. Michael Gibson, Freek W.A. Verheugt November 01, 2016
Presentation TCT 2016 The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus DAPT Presenter: David P. Faxon, C. Michael Gibson, Christopher B. Granger November 01, 2016